Soaring Avastin Sales Boost Genentech's Third-Quarter Earnings

Drug Industry Daily
KEYWORDS Markets
A A

Rising demand for Genentech’s two main cancer drugs — Avastin and Herceptin — drove up the biotech firm’s third-quarter earnings by more than 50 percent.

To View This Article:

Login

Subscribe To Drug Industry Daily